Table 1 Comparison of characteristics between pancreatic and non-pancreatic metastasis from RCC (n = 262)

Male/female

n (%)

12/8

(60%/40%)

184/58

(76%/24%)

0.11

Age at Dx of RCC*

59.7

(52.5–62.5)

61.7

(54.6-69.3)

0.16

Age at Dx of metastasis

66.2

(62.3–69.9)

63.6

(56.4-70.2)

0.09

Metastatic sites

n (%)

Pancreas

20

(100%)

0

(0%)

Lung

4

(20%)

194

(80%)

<0.0001

Bone

0

(0%)

63

(26%)

0.009

Kidney

5

(25%)

2

(1%)

<0.0001

Lymph nodes

3

(15%)

77

(32%)

0.117

Liver

3

(15%)

19

(8%)

0.268

Adrenal gland

2

(10%)

39

(16%)

0.469

Synchronous: metachronous (n)

3 /17

(15%/85%)

153/89

(63%/37%)

<0.0001

Period from Dx of RCC to metastasis (years)*

7.8

(4.2–12.7)

0

(0–0.7)

<0.0001

Metastasectomy (n)

(Yes/No)

15/5

(75%/25%)

56/186

(23%/77%)

<0.0001

Molecular targeted therapy (n)

(Yes/No)

6/14

(30%/70%)

98/144

(40%/60%)

0.357

Median OS from the Dx of metastasis (years)^#

Not reached

2.7

(1.8-3.6)

<0.0001